Figure Legends:

Figure S1a. Weight change from baseline over the course of the 16-week trial for patients completing the trial. Mean values for carriers of the *DRD2* -141C deletion allele are depicted in red; non-carriers are depicted in blue. Values are corrected for medication assignment (OLZ/RIS) and race (Caucasian/non-Caucasian). Univariate factorial ANOVA reveals a significant main effect of genotype ($F_{1,25}$=5.5, p=.031).

Figure S1b. BMI change from baseline over the course of the 16-week trial for patients completing the trial. Mean values for carriers of the *DRD2* -141C deletion allele are depicted in red; non-carriers are depicted in blue. Values are corrected for medication assignment (OLZ/RIS) and race (Caucasian/non-Caucasian). Univariate factorial ANOVA reveals a trend for main effect of genotype ($F_{1,25}$=4.0, p=.06).

Figure S1c. Weight change from baseline over the course of the 16-week trial for patients completing the trial. Mean values for homozygotes of the *DRD2* -141C deletion allele are depicted in red; heterozygotes are in purple; non-carriers are depicted in blue. Values are corrected for medication assignment (OLZ/RIS) and race (Caucasian/non-Caucasian). Univariate factorial ANOVA reveals a trend for main effect of genotype ($F_{2,25}$=3.1, p=.073).

Figure S1d. BMI change from baseline over the course of the 16-week trial for patients completing the trial. Mean values for homozygotes of the *DRD2* -141C deletion allele are depicted in red; heterozygotes are in purple; non-carriers are depicted in blue. Values are corrected for medication assignment (OLZ/RIS) and race (Caucasian/non-Caucasian). Univariate factorial ANOVA reveals a nonsignificant main effect of genotype ($F_{2,25}$=2.3, p=.132).

Figure S2a. Weight change from baseline over the course of the first six weeks of the trial. Mean values for carriers of the *DRD2* -141C deletion allele are depicted in red; non-carriers are depicted in blue. Values are corrected for medication assignment (OLZ/RIS) and race (Caucasian/non-Caucasian). Univariate factorial ANOVA reveals a significant main effect of genotype ($F_{1,33}$=5.1, p=.032).

Figure S2b. BMI change from baseline over the course of the first six weeks of the trial. Mean values for carriers of the *DRD2* -141C deletion allele are depicted in red; non-carriers are depicted in blue. Values are corrected for medication assignment (OLZ/RIS) and race (Caucasian/non-Caucasian). Univariate factorial ANOVA reveals a significant main effect of genotype ($F_{1,33}$=4.8, p=.038).

Figure S2c. Weight change from baseline over the course of the first six weeks of the trial. Mean values for homozygotes of the *DRD2* -141C deletion allele are depicted in red; heterozygotes are in purple; non-carriers are depicted in blue. Values are corrected for medication assignment (OLZ/RIS) and race (Caucasian/non-Caucasian). Univariate factorial ANOVA reveals a trend for main effect of genotype ($F_{2,33}$=2.9, p=.073).

Figure S2d. BMI change from baseline over the course of the the first six weeks of the trial. Mean values for homozygotes of the *DRD2* -141C deletion allele are depicted in red; heterozygotes are in purple; non-carriers are depicted in blue. Values are corrected for medication assignment (OLZ/RIS) and race (Caucasian/non-Caucasian). Univariate factorial ANOVA reveals a trend for main effect of genotype ($F_{2,33}$=2.7, p=.086).



Figure S1a



Figure S1b



Figure S1c



Figure S1d



Figure S2a



Figure S2b



Figure S2c



Figure S2d